Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial

What is it about?

Few options are available for patients who have failed five treatments for their depression. This small open-label study demonstrated significant safety and efficacy of synthetic psilocybin in severe treatment resistant depression and supports further study of psychedelics for this often neglected population.

Featured Image